These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 24367026)

  • 1. Generation of multiple fluid-phase C3b:plasma protein complexes during complement activation: possible implications in C3 glomerulopathies.
    Ramadass M; Ghebrehiwet B; Smith RJ; Kew RR
    J Immunol; 2014 Feb; 192(3):1220-30. PubMed ID: 24367026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection.
    Fearon DT; Daha MR; Strom TB; Weiler JM; Carpenter CB; Austen KF
    Transplant Proc; 1977 Mar; 9(1):729-39. PubMed ID: 325806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3.
    Pangburn MK; Schreiber RD; Müller-Eberhard HJ
    J Exp Med; 1981 Sep; 154(3):856-67. PubMed ID: 6912277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced recognition of plasma proteins in a non-native state by complement C3b. A possible clearance mechanism for damaged proteins in blood.
    Ramadass M; Ghebrehiwet B; Kew RR
    Mol Immunol; 2015 Mar; 64(1):55-62. PubMed ID: 25466612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation.
    Martínez-Barricarte R; Heurich M; Valdes-Cañedo F; Vazquez-Martul E; Torreira E; Montes T; Tortajada A; Pinto S; Lopez-Trascasa M; Morgan BP; Llorca O; Harris CL; Rodríguez de Córdoba S
    J Clin Invest; 2010 Oct; 120(10):3702-12. PubMed ID: 20852386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of vaccinia virus complement control protein with human complement proteins: factor I-mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway.
    Sahu A; Isaacs SN; Soulika AM; Lambris JD
    J Immunol; 1998 Jun; 160(11):5596-604. PubMed ID: 9605165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel CFHR1-CFHR5 hybrid leads to a familial dominant C3 glomerulopathy.
    Togarsimalemath SK; Sethi SK; Duggal R; Le Quintrec M; Jha P; Daniel R; Gonnet F; Bansal S; Roumenina LT; Fremeaux-Bacchi V; Kher V; Dragon-Durey MA
    Kidney Int; 2017 Oct; 92(4):876-887. PubMed ID: 28729035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C5 nephritic factors drive the biological phenotype of C3 glomerulopathies.
    Marinozzi MC; Chauvet S; Le Quintrec M; Mignotet M; Petitprez F; Legendre C; Cailliez M; Deschenes G; Fischbach M; Karras A; Nobili F; Pietrement C; Dragon-Durey MA; Fakhouri F; Roumenina LT; Fremeaux-Bacchi V
    Kidney Int; 2017 Nov; 92(5):1232-1241. PubMed ID: 28712854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus.
    Waldo FB; Forristal J; Beischel L; West CD
    J Clin Invest; 1985 Jun; 75(6):1786-95. PubMed ID: 3159752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phosphorylation of C3 by a casein kinase released from activated human platelets increases opsonization of immune complexes and binding to complement receptor type 1.
    Nilsson-Ekdahl K; Nilsson B
    Eur J Immunol; 2001 Apr; 31(4):1047-54. PubMed ID: 11298329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relation of putative thioester bond in C3 to activation of the alternative pathway and the binding of C3b to biological targets of complement.
    Pangburn MK; Müller-Eberhard HJ
    J Exp Med; 1980 Oct; 152(4):1102-14. PubMed ID: 6903192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies.
    Servais A; Noël LH; Roumenina LT; Le Quintrec M; Ngo S; Dragon-Durey MA; Macher MA; Zuber J; Karras A; Provot F; Moulin B; Grünfeld JP; Niaudet P; Lesavre P; Frémeaux-Bacchi V
    Kidney Int; 2012 Aug; 82(4):454-64. PubMed ID: 22456601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glomerular paramesangial deposits: association with hypocomplementemia in membranoproliferative glomerulonephritis types I and III.
    West CD; McAdams AJ
    Am J Kidney Dis; 1998 Mar; 31(3):427-34. PubMed ID: 9506679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initiation of the alternative complement pathway due to spontaneous hydrolysis of the thioester of C3.
    Pangburn MK; Müller-Eberhard HJ
    Ann N Y Acad Sci; 1983; 421():291-8. PubMed ID: 6586103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN.
    Iatropoulos P; Daina E; Curreri M; Piras R; Valoti E; Mele C; Bresin E; Gamba S; Alberti M; Breno M; Perna A; Bettoni S; Sabadini E; Murer L; Vivarelli M; Noris M; Remuzzi G; ;
    J Am Soc Nephrol; 2018 Jan; 29(1):283-294. PubMed ID: 29030465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.
    Noris M; Donadelli R; Remuzzi G
    Pediatr Nephrol; 2019 Aug; 34(8):1311-1323. PubMed ID: 29948306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of C3b(2)--IgG complexes with complement proteins properdin, factor B and factor H: implications for amplification.
    Jelezarova E; Vogt A; Lutz HU
    Biochem J; 2000 Jul; 349(Pt 1):217-23. PubMed ID: 10861231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A C3 convertase assay for nephritic factor functional activity.
    Jelezarova E; Schlumberger M; Sadallah S; Späth PJ; Schifferli JA; Lutz HU
    J Immunol Methods; 2001 May; 251(1-2):45-52. PubMed ID: 11292480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.
    Mayes JT; Schreiber RD; Cooper NR
    J Clin Invest; 1984 Jan; 73(1):160-70. PubMed ID: 6418767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formation of high-affinity C5 convertases of the alternative pathway of complement.
    Rawal N; Pangburn M
    J Immunol; 2001 Feb; 166(4):2635-42. PubMed ID: 11160326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.